An 18-Week Multi-Center Randomized Double-Blind Placebo-Controlled Parallel-Group Study Of The Efficacy Safety And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Trial Profile

An 18-Week Multi-Center Randomized Double-Blind Placebo-Controlled Parallel-Group Study Of The Efficacy Safety And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Donepezil (Primary)
  • Indications Cognition disorders; Vascular dementia
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 22 Feb 2008 Results were presented at the 2008 American Stroke Association's International Stroke Conference.
    • 04 Oct 2007 Status change from in progress to completed.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top